Evan Seigerman, an analyst from BMO Capital, maintained the Buy rating on Eli Lilly & Co. The associated price target remains the same with $1,200.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Evan Seigerman has given his Buy rating due to a combination of factors that highlight Eli Lilly & Co’s promising future. The TRIUMPH-4 trial results for retatrutide have exceeded expectations, showing significant weight loss and pain reduction, which strengthens the drug’s profile and potential market impact. The trial demonstrated a placebo-adjusted weight loss of 26.6% at the highest dose, alongside a notable reduction in WOMAC pain scores, indicating strong efficacy in treating osteoarthritis.
Moreover, Eli Lilly’s strategic pipeline, particularly in diabetes and oncology, is expected to drive sustained growth. The recent approval of donanemab further supports the company’s growth prospects, positioning it well against its peers. Despite some concerns about tolerability, such as dysesthesia, the overall results are impressive and suggest a positive reaction in the market, reinforcing the Buy recommendation.
In another report released today, Citi also maintained a Buy rating on the stock with a $1,500.00 price target.
LLY’s price has also changed moderately for the past six months – from $808.610 to $1009.380, which is a 24.83% increase.